Neurocrine biosciences reports third quarter 2024 financial results and raises 2024 ingrezza sales guidance

Ingrezza® (valbenazine) third quarter net product sales of $613 million representing 26% year-over-year growth ingrezza ® (valbenazine) 2024 net product sales guidance raised to $2.30 - $2.32 billion board authorizes $300 million share repurchase plan san diego , oct. 30, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the third quarter ended september 30, 2024 and provided an update on its 2024 financial guidance. "with continued ingrezza growth across the tardive dyskinesia and huntington's disease chorea indications, fda priority review for crinecerfont in congenital adrenal hyperplasia, a deep neuroscience focused pipeline and a strong balance sheet, we are confident in our ability to help more patients than ever before," said kyle w.
NBIX Ratings Summary
NBIX Quant Ranking